APTO - Aptose Biosciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4300
0.0000 (0.00%)
At close: 04:00PM EDT
0.4300 0.00 (0.00%)
After hours: 06:43PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4300
Open0.4276
Bid0.4101 x 1100
Ask0.4395 x 3000
Day's Range0.4100 - 0.4400
52 Week Range0.3600 - 1.0000
Volume329,581
Avg. Volume225,725
Market Cap40.53M
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.5000
Earnings DateJul 31, 2023 - Aug 04, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APTO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

    EHA Abstract on Tuspetinib and Venetoclax Recently PublishedSAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the company management team will provide a clinical update on Saturday, June 10, 2023, at 12:00 PM EST / 6:00 PM CEST, in conjunction with EHA 2023 Inte

  • GlobeNewswire

    Aptose Enters into $25 Million Committed Equity Facility

    SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The agreement governs a Committed Equity Facility that provides Aptose the right, in its sol

  • GlobeNewswire

    Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

    SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that, at the Company’s annual and special meeting of shareholders held today, May 23, 2023 (the “Meeting”), the proposed reverse stock split (the “Reverse Stock Split”) of the Company’s common shares (the “Common Shar

  • InvestorPlace

    3 Stocks With 1,000% Upside Potential

    If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high. Such catalysts include promising drug candidates that are awaiting approval or going through a clinical trial. These catalysts may or may not materialize for years. If the said business disappoints by losing the drug or not getting approval, share

  • Simply Wall St.

    Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability

    Aptose Biosciences Inc. ( TSE:APS ) is possibly approaching a major achievement in its business, so we would like to...

  • GlobeNewswire

    Aptose Reports Results for the First Quarter 2023

    ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Refractory AML Patients in APTIVATE Expansion Trial ─ ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial; Early Clinical Activity Already Noted ─ ─ Tuspetinib Superior Safety Profile Continues ─ ─ Luxepti

  • GlobeNewswire

    Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference

    SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2023 Global Healthcare Conference on May 17, 2023. The Aptose management team also will be hosting one-

  • GlobeNewswire

    Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023

    SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Monday, May 8, 2023Time:5:00 PM ETAudio Webcast Only:linkQ&A Part

  • GlobeNewswire

    Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference

    SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023. The Aptose managemen

  • GlobeNewswire

    Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium

    SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format. The Cantor Healthcare Research team will be hosting a series of insightful fireside chats

  • Zacks

    Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?

    Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.

  • Insider Monkey

    Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript

    Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Hello and thank you for standing by and welcome to Aptose Biosciences reports for the Fourth Quarter and Yearend 2022 Conference Call. At this time, all participants on a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. I […]

  • GlobeNewswire

    Aptose Reports Results for the Fourth Quarter and Full Year 2022

    ─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stag

  • GlobeNewswire

    Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

    SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank (“SVB”) and questions raised by interested parties. Aptose has not entered into a line of credit with SVB, and therefore has no exposure related to any credit facility. Aptose he

  • GlobeNewswire

    Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

    SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Thursday, March 23, 2023 Time: 5:00 PM E

  • GlobeNewswire

    Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

    SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format. Oppenheimer 33rd Annual Healthcare Confere

  • GlobeNewswire

    Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

    • AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnost

  • Simply Wall St.

    We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

    SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA. Conference Presentation D

  • GlobeNewswire

    Aptose Biosciences Establishes New At-The-Market Facility

    SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with JonesTrading Institutional Services LLC, as agent (the “Agent”). Under the terms of the Equity Distribution Agreement,

  • GlobeNewswire

    Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

    Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet Combination, Maintenance Therapy, and Patients Failed by Prior FLT3 InhibitorsTuspetinib Enrolling APTIVATE Expansion Trial for Monotherapy and Combination TherapyLuxeptinib Original Formulation Delivers New CR in DLBCL PatientLuxeptinib New G3 Form

  • GlobeNewswire

    Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

    Data to be presented in poster at ASH Annual MeetingSAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company’s management team will provide a corporate update on Sunday, December 11, 2022, at 10:00 AM EST / 9:00 CST, in conjunction with poster presentati

  • GlobeNewswire

    Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

    SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) ac

  • GlobeNewswire

    Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

    Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster PresentationSAN DIEGO and TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tuspetinib (formerly HM43239), a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid inhibitor, have been accepted for poster pres

  • GlobeNewswire

    Aptose Reports Results for the Third Quarter 2022

    ─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Open for Tuspetinib Dose Expansion Trial with Enriched Populations ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib to Begin Soon ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences